BAL0891 is a first-in-class mitotic checkpoint inhibitor that pushes cells through mitosis without adequate time for correct chromosome segregation. This results in aberrant tumor cell division leading to tumor cell death.
The compound is a unique dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). The dual action of BAL0891 leads to rapid disruption of the mitotic spindle assembly checkpoint (SAC) driving the cells through mitosis before the chromosomes are properly aligned leading to premature cell division and tumor cell death.
BAL0891 has shown anti-proliferative activity across diverse tumor cell lines in vitro and single agent efficacy in in vivo models of solid human cancers.